You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 21 - 30 of 205243 results
  1. Development of a Dual-Targeting ClpP Activating Antibiotic

    SBC: ARIETIS CORPORATION            Topic: NIAID

    The World Health Organization has declared that antimicrobial resistance is one of the biggest threats to global health. It was estimated that by 2050, deaths due to drug resistant bacteria will exceed those caused by cancer. The goal of this project is to develop a new ureadepsipeptide antibiotic (UDEP) to treat infections caused by Gram-positive pathogens, such as bacteremia, pneumonia, endocard ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a regional anesthesia guidance system to increase patient access to opioid-sparing analgesia for hip fracture pain

    SBC: RIVANNA MEDICAL, INC.            Topic: NIAMS

    PROJECT SUMMARY/ABSTRACT For the rt330,000 Americans that are hospitalized for hip fractures yearly, rapid treatment of pain and surgical intervention is critical to recover mobility and reduce the risk of death. Parenteral opioids are the standard of care to manage acute hip fracture pain but increase the risk of adverse events and outcomes, including delirium and recurrent opioid use. Ultrasound ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. IND-enabling Preclinical Development of a Sustained-release Pritelivir Intravaginal ring for the Treatment and Prophylaxis of Genital Herpes

    SBC: AURITEC PHARMACEUTICALS, INC.            Topic: NIAID

    SUMMARY The broad, long-term goal of this project is to develop a pritelivir intravaginal ring (IVR) for the treatment and pre-exposure prophylaxis of genital herpes, a common problem that affects more than 30 million Americans. Recurrences are common and may be painful, and infection is life-long, yet few treatment options exist. Pritelivir is a promising α-helicase inhibitor that has been prove ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. SAGE LEAF 2: An Online Self-Guided Positive Emotion Regulation Program to Reduce Alzheimer's Dementia Caregiver Burden Delivered through Caregiver-Serving Organizations

    SBC: BRIGHTOUTCOME INC.            Topic: NIA

    Project Summary In the US alone, more than 11 million family caregivers provide care for someone with Alzheimer's disease or other dementia on a daily basis.1 These family caregivers have been estimated to shoulder 70% of the total cost of care over their care recipient’s lifetime, costs which include medical bills and unpaid caregiving hours.2 Caregiving-related stress contributes to social iso ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Eliminating Ventricular Tachycardia: Pivotal Clinical Trial using the Durablate® Catheter

    SBC: Thermedical Inc.            Topic: NHLBI

    Ventricular tachycardia (VT) causes more than half of the 170,000–450,000 sudden cardiac deaths (SCD) that occur annually in the United States. Implantable cardioverter defibrillators (ICDs) are the standard of care, but they are expensive (the total cost of an ICD implant exceeds $50,000) and not curative. Patients who receive ICDs are subject to shocks to halt episodes of VT, and those shocks ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass

    SBC: OMNIOX INC            Topic: NICHD

    1. PROJECT SUMMARY/ABSTRACT Omniox is developing a unique oxygen delivery protein, OMX, as a treatment to preserve myocardial and peripheral organ function and significantly reduce morbidity after neonatal cardiopulmonary bypass (CPB) during surgical correction of congenital heart disease (CHD). Of the ~40,000 children born annually with CHD, ~10,000 require urgent surgery to repair heart defects1 ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Clinic-Ready MACH-1 Gene Gun for delivery of a universal influenza DNA vaccine

    SBC: ORLANCE INC            Topic: NIAID

    PROJECT SUMMARY Orlance has developed a lead universal influenza (UFlu) DNA vaccine to address the need for a vaccine that can protect from annual influenza and the emergence of new variants that could cause future pandemics. Our UFlu vaccine is a multi-dose vaccine designed to induce systemic and mucosal immune responses that can prevent transmission and minimize disease from currently circulatin ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Boron-containing antimalarial drug discovery

    SBC: REACTIVE BIOSCIENCES INC            Topic: NIAID

    PROJECT SUMMARY New drugs to treat malaria, ideally with unique chemical structures and mechanisms of action, are urgently needed. Optimal drug candidates for the treatment and prevention of malaria will have potent activity against cultured parasites and in animal models of malaria, be rapidly active against erythrocytic malaria parasites, be orally bioavailable, have extended pharmacological exp ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Rapid response to pandemic influenza via multi-antigen RNA-based vaccine

    SBC: TIBA BIOTECH LLC            Topic: NIAID

    Project Abstract Avian influenza A H7N9 causes severe respiratory illness with a high mortality rate, and its zoonotic capacity has raised serious concerns over the possibility of a pandemic. The value of vaccines for pandemic-potential viruses has been demonstrated by the devastating effects of COVID-19 on human health and the economy. Development of H7 Influenza vaccines has lagged, as pandemic ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Biomarker-Based Test of Cure for Chagas Disease

    SBC: KEPHERA DIAGNOSTICS LLC            Topic: NIAID

    Project Summary Chagas disease, caused by infection with Trypanosoma cruzi, is the most prevalent parasitic disease in the western hemisphere, infecting 8-11 million individuals and with over 70 million at risk. The infection is transmitted by an insect vector, but can also be acquired through blood transfusion, organ transplant, or congenitally. Following a brief acute phase, the parasite persist ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government